Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

Immunosuppression is a well-described risk factor for cutaneous squamous cell carcinoma (CSCC), and PD-L1 expression has been observed in advanced CSCC. In this Medtalk, Paolo Antonio Ascierte, MD, evaluates and describes the clinical experience with checkpoint inhibition and the current landscape in immuno-oncology treatment.